Bone Biologics Corporation
BBLG
$2.16
-$0.04-1.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.14M | 2.05M | 2.09M | 2.35M | 2.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.29M | 4.35M | 4.22M | 3.82M | 4.95M |
| Operating Income | -4.29M | -4.35M | -4.22M | -3.82M | -4.95M |
| Income Before Tax | -4.22M | -4.26M | -4.11M | -4.14M | -5.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.22 | -4.26 | -4.11 | -4.14 | -5.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.22M | -4.26M | -4.11M | -4.14M | -5.12M |
| EBIT | -4.29M | -4.35M | -4.22M | -3.82M | -4.95M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -21.14 | -23.83 | -29.78 | -46.36 | -61.54 |
| Normalized Basic EPS | -6.34 | -8.03 | -11.74 | -18.71 | -35.07 |
| EPS Diluted | -21.14 | -23.83 | -29.78 | -46.36 | -61.54 |
| Normalized Diluted EPS | -6.34 | -8.03 | -11.74 | -18.71 | -35.07 |
| Average Basic Shares Outstanding | 1.79M | 1.43M | 1.01M | 673.70K | 446.80K |
| Average Diluted Shares Outstanding | 1.79M | 1.43M | 1.01M | 673.70K | 446.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |